Pelthos 10-Q Discloses Unremediated Material Weakness and Restatement Alongside Q3 Results
PTHS is trading near its 52-week low of $8.72 (7.7% above the low).
Summary
Pelthos' Q3 10-Q shows Zelsuvmi revenue doubling to $15.2 million and the net loss narrowing to $7.9 million, but also discloses an unremediated material weakness in convertible-note fair-value accounting that forced a restatement of Q1 2026.
Key Events · Earnings and Guidance · PTHS
-
Material Weakness Disclosed, Still Unremediated
Management concluded internal control over financial reporting was not effective as of September 30, 2026 due to a misapplication of ASC 820 on the November 2025 convertible notes; the weakness has not been remediated.
-
Q1 2026 Financials Restated
The March 31, 2026 quarter was restated via a 10-Q/A filed August 13, 2026, and disclosure controls were also deemed not effective at September 30, 2026.
-
Zelsuvmi Revenue Doubles, Loss Narrows
Q3 net product revenue was $15.2 million versus $7.1 million a year earlier; net loss fell to $7.9 million from $23.4 million in Q2 2026, while the nine-month loss was $56.4 million.
-
Runway Rests on Zelsuvmi, Not the Merger
$17.7 million of cash at September 30 plus the $10.0 million drawn October 30, 2026 is projected to fund a year of operations; management excluded the Castle Creek merger and $57.5 million PIPE from that going-concern conclusion.
Analysis · PTHS · Life Sciences
The earnings numbers were already out this morning, but the 10-Q carries the more consequential news: management says its internal control over financial reporting was not effective at September 30, 2026 because of a misapplication of ASC 820 fair-value guidance on the November 2025 convertible notes, which forced a restatement of the March 31, 2026 quarter. That weakness remains unremediated — the company swapped valuation firms in Q3 but has not closed the gap. The operating story, by contrast, is improving: Zelsuvmi revenue of $15.2 million in Q3 versus $7.1 million a year ago, and the net loss narrowed to $7.9 million from $23.4 million in Q2. Cash of $17.7 million plus the $10.0 million drawn on October 30, 2026 is enough for twelve months, but only on the company's own sales forecast — and management explicitly did not count the Castle Creek merger or the $57.5 million PIPE in that math, so the runway conclusion rests on Zelsuvmi alone. Note the $9.3 million nine-month hit from remeasuring the convertible notes is a non-cash mark-to-market swing, not new dilution or cash out the door.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTHS was trading at $9.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.9M. The 52-week trading range was $8.72 to $37.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.